AU2002232387A1 - Method for introducing antisense oligonucleotides into eucaryotic cells - Google Patents

Method for introducing antisense oligonucleotides into eucaryotic cells

Info

Publication number
AU2002232387A1
AU2002232387A1 AU2002232387A AU3238702A AU2002232387A1 AU 2002232387 A1 AU2002232387 A1 AU 2002232387A1 AU 2002232387 A AU2002232387 A AU 2002232387A AU 3238702 A AU3238702 A AU 3238702A AU 2002232387 A1 AU2002232387 A1 AU 2002232387A1
Authority
AU
Australia
Prior art keywords
lipid
alkyl
group
cells
unsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002232387A
Other languages
English (en)
Inventor
Donna K. Fox
Gulilat Gebeyehu
Martha K. Ogilvie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Invitrogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invitrogen Corp filed Critical Invitrogen Corp
Publication of AU2002232387A1 publication Critical patent/AU2002232387A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2002232387A 2000-10-27 2001-10-26 Method for introducing antisense oligonucleotides into eucaryotic cells Abandoned AU2002232387A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24306900P 2000-10-27 2000-10-27
US60/243,069 2000-10-27
PCT/US2001/042788 WO2002034879A2 (fr) 2000-10-27 2001-10-26 Procede d'introduction d'oligonucleotides antisens dans des cellules eucaryotes

Publications (1)

Publication Number Publication Date
AU2002232387A1 true AU2002232387A1 (en) 2002-05-06

Family

ID=22917238

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002232387A Abandoned AU2002232387A1 (en) 2000-10-27 2001-10-26 Method for introducing antisense oligonucleotides into eucaryotic cells

Country Status (7)

Country Link
US (2) US20020086849A1 (fr)
EP (1) EP1337664A4 (fr)
JP (1) JP2004521614A (fr)
AU (1) AU2002232387A1 (fr)
CA (1) CA2427068A1 (fr)
NZ (1) NZ525440A (fr)
WO (1) WO2002034879A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1624068A1 (fr) * 1993-06-01 2006-02-08 Life Technologies Inc. Vaccination génétique avec des lipides cationiques
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) * 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US20030069173A1 (en) 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
EP1829856A3 (fr) 1998-11-12 2009-02-25 Invitrogen Corporation Réactifs de transfection
JP4722481B2 (ja) 2002-06-28 2011-07-13 プロティバ バイオセラピューティクス リミテッド リポソーム製造方法および装置
JP4842821B2 (ja) * 2003-09-15 2011-12-21 プロチバ バイオセラピューティクス インコーポレイティッド ポリエチレングリコール修飾脂質化合物およびその使用
US7799565B2 (en) * 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
AU2005306533B2 (en) * 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
EP2395012B8 (fr) 2005-11-02 2018-06-06 Arbutus Biopharma Corporation Molécules d'ARNsi modifiées et leurs utilisations
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
ES2535419T3 (es) * 2007-12-27 2015-05-11 Protiva Biotherapeutics Inc. Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
CA3044134A1 (fr) * 2008-01-02 2009-07-09 Arbutus Biopharma Corporation Compositions et procedes ameliores pour la delivrance d'acides nucleiques
DK2279254T3 (en) 2008-04-15 2017-09-18 Protiva Biotherapeutics Inc PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
CN102245590B (zh) 2008-10-09 2014-03-19 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
EP2405921A4 (fr) 2009-01-26 2013-05-22 Protiva Biotherapeutics Inc Compositions et procédés d'inactivation de l'expression de l'apolipoprotéine c-iii
WO2011000106A1 (fr) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Lipides cationiques et procédés améliorés pour l'administration d'agents thérapeutiques
IL292615B2 (en) 2009-07-01 2023-11-01 Protiva Biotherapeutics Inc Nucleic acid-lipid particles, preparations containing them and their uses
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8716464B2 (en) * 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
US8455455B1 (en) 2010-03-31 2013-06-04 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes involved in hemorrhagic fever
WO2012000104A1 (fr) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Systèmes non liposomaux pour une administration d'acide nucléique
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP3169310A1 (fr) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions comprenant des agrégats lipidiques et procédés d'administration efficace de molécules dans des cellules
EP3956470A1 (fr) 2019-04-16 2022-02-23 Genfit Compositions et procédés de stabilisation de marn
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5514787A (en) * 1989-07-21 1996-05-07 Washington University DNA sequences encoding human membrane cofactor protein (MCP)
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5506212A (en) * 1990-01-11 1996-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5514577A (en) * 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5541307A (en) * 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5543507A (en) * 1992-03-05 1996-08-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
US5916807A (en) * 1992-03-16 1999-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
AU4674393A (en) * 1992-07-20 1994-02-14 Isis Pharmaceuticals, Inc. Pseudo-half-knot rna formation by hybridization of antisense oligonucleotides to target rna's secondary structure
ATE162198T1 (de) * 1992-07-27 1998-01-15 Hybridon Inc Oligonukleotid alkylphosphonothiate
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US6041094A (en) * 1993-05-07 2000-03-21 Russell; Donald G. Intermediate density marker and a method using such a marker for radiographic examination
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US5519134A (en) * 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) * 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5510476A (en) * 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5693773A (en) * 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
IL122290A0 (en) * 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
US6086913A (en) * 1995-11-01 2000-07-11 University Of British Columbia Liposomal delivery of AAV vectors
US5595096A (en) * 1996-01-04 1997-01-21 Coffman; George L. English-metric wrench socket or drive
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6320017B1 (en) * 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers

Also Published As

Publication number Publication date
US20060147514A1 (en) 2006-07-06
WO2002034879A2 (fr) 2002-05-02
US20020086849A1 (en) 2002-07-04
CA2427068A1 (fr) 2002-05-02
EP1337664A4 (fr) 2005-01-19
EP1337664A2 (fr) 2003-08-27
NZ525440A (en) 2005-03-24
WO2002034879A3 (fr) 2003-01-30
JP2004521614A (ja) 2004-07-22

Similar Documents

Publication Publication Date Title
AU2002232387A1 (en) Method for introducing antisense oligonucleotides into eucaryotic cells
Heyes et al. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
US5674908A (en) Highly packed polycationic ammonium, sulfonium and phosphonium lipids
ES2949172T3 (es) Método de encapsulamiento de un ácido nucleico en un hospedante de nanopartículas lipídicas
EP1129064B1 (fr) Reactifs de transfection
EP1019365B1 (fr) Nouvelles compositions d'administration de molecules chargees negativement
US5851548A (en) Liposomes containing cationic lipids and vitamin D
US6008202A (en) Stable lipid-comprising drug delivery complexes and methods for their production
WO2019089828A1 (fr) Nanoparticules lipidiques lamellaires
AU710170B2 (en) Cationic virosomes as transfer system for genetic material
US5739271A (en) Thiocationic lipids
CN103987847A (zh) 胺阳离子脂质及其用途
WO2002100435A1 (fr) Compositions et methodes permettant de favoriser le transfert d'acide nucleique dans des cellules
US6074667A (en) Liposomal transfection method
Bennett et al. Considerations for the design of improved cationic amphiphile-based transfection reagents
WO2023064513A2 (fr) Compositions de trem et procédés d'utilisation
US5759519A (en) Method for the intracellular delivery of biomolecules using thiocationic lipids
KR100373845B1 (ko) 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
Surovoy et al. A novel series of serum-resistant lipoaminoacid compounds for cellular delivery of plasmid DNA
AU2021281453A1 (en) Trem compositions and methods relating thereto
EP0871758B1 (fr) Procede de transfection par liposomes
KR100373844B1 (ko) 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
Wagner Structure—Activity Relationships in Cell Culture

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application